CanBas Co., Ltd. (4575.T)
JPY 907.0
(-1.2%)
JPY 907.0
(-1.2%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.88 Billion JPY | -16.71% |
| 2022 | -1.61 Billion JPY | -336.73% |
| 2021 | -370.43 Million JPY | 8.48% |
| 2020 | -404.76 Million JPY | -11.71% |
| 2019 | -362.34 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | -1.88 Billion JPY | -16.71% |
| 2023 Q4 | -1.88 Billion JPY | 26.2% |
| 2023 Q3 | -2.55 Billion JPY | 7.98% |
| 2023 Q2 | -2.78 Billion JPY | -4.79% |
| 2023 Q1 | -2.65 Billion JPY | -64.01% |
| 2022 Q4 | -1.61 Billion JPY | -17.15% |
| 2022 Q3 | -1.38 Billion JPY | 29.9% |
| 2022 Q2 | -1.97 Billion JPY | -37.74% |
| 2022 Q1 | -1.43 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 354.214% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -66.516% |
| GNI Group Ltd. | -17.93 Billion JPY | 89.471% |
| Linical Co., Ltd. | -4.46 Billion JPY | 57.695% |
| Trans Genic Inc. | -221.16 Million JPY | -753.736% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 57.028% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 60.581% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 231.716% |
| AnGes, Inc. | -3.79 Billion JPY | 50.281% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -348.709% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 107.581% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -279.039% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -304.892% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 30.225% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -92.253% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 44.416% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -82.513% |
| Kidswell Bio Corporation | 343.58 Million JPY | 649.552% |
| PeptiDream Inc. | 3.29 Billion JPY | 157.357% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -94.141% |
| Ribomic Inc. | -2.09 Billion JPY | 10.075% |
| SanBio Company Limited | -3.78 Billion JPY | 50.176% |
| Healios K.K. | -2.19 Billion JPY | 13.781% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -99.839% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 28.045% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -33.248% |
| StemRIM | -8.41 Billion JPY | 77.548% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 59.684% |
| FunPep Company Limited | -1.79 Billion JPY | -5.287% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 11.621% |
| Stella Pharma Corporation | -1.11 Billion JPY | -68.679% |
| TMS Co., Ltd. | -3.44 Billion JPY | 45.216% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 66.013% |
| Cuorips Inc. | -5.56 Billion JPY | 66.046% |
| K Pharma,Inc. | -3.26 Billion JPY | 42.193% |
| Takara Bio Inc. | -32.2 Billion JPY | 94.137% |
| ReproCELL Incorporated | -2.93 Billion JPY | 35.755% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -185.675% |
| StemCell Institute Inc. | -2.83 Billion JPY | 33.438% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 8.621% |
| CellSeed Inc. | -2.01 Billion JPY | 6.155% |